Author Letsch, Anne

1 to 20 of 20 Items

2012 | Conference Abstract
Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups
Reinwald, M.; Nowak, D.; Platzbecker, U.; Giagounidis, A. A. N.; Goetze, K. S.; Ottmann, O. G. & Haase, D. et al. (2012)
Blood, 120(21) 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA.
Washington: Amer Soc Hematology.
Details WoS

2013 | Conference Abstract
TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q) treated with lenalidomide: Results from the German Le-Mon-5 trial
Mossner, M.; Platzbecker, U.; Giagounidis, A. A. N.; Goetze, K.; Letsch, A.; Haase, D. & Schlenk, R. F. et al. (2013)
Leukemia Research, 37
Oxford: Pergamon-elsevier Science Ltd.
Details WoS

2013 | Conference Abstract
Did the prognosis of MDS patients improve during the last 30 years?
Neukirchen, J.; Nachtkamp, K.; Pfeilstoecker, M.; Valent, P.; Stauder, R.; Blum, S. & Luebbert, M. et al. (2013)
Leukemia Research, 37
Oxford: Pergamon-elsevier Science Ltd.
Details WoS

2013 | Conference Abstract
454 next generation sequencing identifies TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q): Results from the German Le-Mon-5 trial
Mossner, M.; Nowak, D.; Platzbecker, U.; Giagounidis, A. A. N.; Goetze, K.; Letsch, A. & Haase, D. et al. (2013)
Onkologie, 36
Basel: Karger.
Details WoS

2013 | Conference Abstract
Improvement of survival of MDS patients during the last 30 years
Neukirchen, J.; Stauder, R.; Pfeilstoecker, M.; Blum, S.; Haase, D.; Luebbert, M. & Hofmann, W.-K. et al. (2013)
Onkologie, 36
Basel: Karger.
Details WoS

2013 | Conference Abstract
Response and progression rate of patients with primary MDS and isolated del(5q), IPSS low/int1 under treatment with lenalidomide
Germing, U.; Giagounidis, A. A. N.; Buesche, G.; Platzbecker, U.; Goetze, K.; Nolte, F. & Schlenk, R. F. et al. (2013)
Leukemia Research, 37
Oxford: Pergamon-elsevier Science Ltd.
Details WoS

2014 | Conference Abstract
Impact of TP53 mutations on the clinical course in patients with MDS and isolated deletion 5(q) treated with Lenalidomid: results from the prospective Le-Mon-5 trial
Mossner, M.; Jann, J.-C.; Launinger-Loersch, E.; Nowak, D.; Platzbecker, U.; Giagounidis, A. A. N. & Goetze, K. et al. (2014)
Oncology Research and Treatment, 37
Basel: Karger.
Details WoS

2014 | Conference Abstract
Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial
Mossner, M.; Jann, J. C.; Launiger-Loersch, E.; Nowak, D.; Platzbecker, U.; Giagounidis, A. A. N. & Goetze, K. S. et al. (2014)
Blood, 124(21)
Washington: Amer Soc Hematology.
Details WoS

2014 | Journal Article | Letter Note
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
Platzbecker, U.; Al-Ali, H. K.; Gattermann, N.; Haase, D.; Janzen, V.; Krauter, J. & Goetze, K. et al. (2014)
Leukemia, 28(3) pp. 696-698. DOI: https://doi.org/10.1038/leu.2013.325
Details DOI PMID PMC WoS

2015 | Conference Abstract
RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)
Schuler, E.; Schemenau, J.; Giagounidis, A. A. N.; Haase, D.; Bueshce, G.; Platzbecker, U. & Nolte, F. et al. (2015)
Leukemia Research, 39 13th International Symposium on Myelodysplastic Syndromes (MDS), Washington, DC.
Oxford: Pergamon-elsevier Science Ltd.
Details WoS

2015 | Conference Abstract
Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment
Jann, J.-C.; Nowak, D.; Nolte, F.; Fey, S.; Nowak, V.; Oblaender, J. & Pressler, J. et al. (2015)
Blood, 126(23) 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL.
Washington: Amer Soc Hematology.
Details WoS

2016 | Conference Abstract
Cytogenetic monitoring from peripheral blood in patients with myelodysplastic syndrome: First results from the German LEMON-5 trial
Braulke, F.; Germing, U.; Schuler, E.; Schulz, X.; Platzbecker, U.; Nolte, F. & Hofmann, W.-K. et al. (2016)
Oncology Research and Treatment, 39
Basel: Karger.
Details WoS

2016 | Journal Article | Letter Note
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
Mossner, M.; Jann, J.-C.; Nowak, D.; Platzbecker, U.; Giagounidis, A. A. N.; Goetze, K. & Letsch, A. et al. (2016)
Leukemia, 30(9) pp. 1956-1959. DOI: https://doi.org/10.1038/leu.2016.111
Details DOI PMID PMC WoS

2017 | Journal Article
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial
Braulke, F. ; Schulz, X. ; Germing, U.; Schuler, E.; Platzbecker, U.; Nolte, F. & Hofmann, W.-K. et al. (2017)
Annals of Hematology, 96(6) pp. 887-894. DOI: https://doi.org/10.1007/s00277-017-2983-0
Details DOI

2017 | Journal Article
Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA
Jann, J.-C.; Nowak, D.; Nolte, F.; Fey, S.; Nowak, V.; Obländer, J. & Pressler, J. et al. (2017)
Journal of Medical Genetics, 54(9) pp. 640-650. DOI: https://doi.org/10.1136/jmedgenet-2017-104528
Details DOI

2018 | Journal Article |
Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities
Emons, G. ; Steiner, E.; Vordermark, D.; Uleer, C.; Bock, N.; Paradies, K. & Ortmann, O. et al. (2018)
Geburtshilfe und Frauenheilkunde, 78(11) pp. 1089-1109. DOI: https://doi.org/10.1055/a-0715-2964
Details DOI

2018 | Journal Article |
Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) – Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer
Emons, G. ; Steiner, E.; Vordermark, D.; Uleer, C.; Bock, N.; Paradies, K. & Ortmann, O. et al. (2018)
Geburtshilfe und Frauenheilkunde, 78(10) pp. 949-971. DOI: https://doi.org/10.1055/a-0713-1218
Details DOI

2020 | Journal Article |
Evaluation of a communication skills training to facilitate addressing palliative care related topics in advanced cancer patients: study protocol of a multicenter randomized controlled trial (PALLI-KOM)
Harnischfeger, N.; Rath, H. M.; Ullrich, A.; Alt-Epping, B. ; Letsch, A.; Thuss-Patience, P. & Bokemeyer, C. et al. (2020)
BMC Palliative Care, 19(1). DOI: https://doi.org/10.1186/s12904-020-00568-3
Details DOI

2021 | Journal Article |
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Hecht, A.; Meyer, J. A.; Jann, J.-C.; Sockel, K.; Giagounidis, A.; Götze, K. S. & Letsch, A. et al. (2021)
Annals of Hematology, 100(6) pp. 1463-1471. DOI: https://doi.org/10.1007/s00277-021-04492-1
Details DOI

2023 | Journal Article
Association between oncologists' death anxiety and their end‐of‐life communication with advanced cancer patients
Harnischfeger, N.; Rath, H. M.; Alt‐Epping, B.; Brand, H.; Haller, K.; Letsch, A. & Rieder, N. et al. (2023)
Psycho-Oncology, art. pon.6132. DOI: https://doi.org/10.1002/pon.6132
Details DOI

Researcher

Göttingen All

Sort

issue date

ASC DESC

Items per Page

10 20 50 100